AFJOG

African Journal of Obstetrics and Gynaecology | Volume 1 | Issue 1 | 2023 | 04 Right choice first time* 1-7 Keep Hormone Therapy Simplewith A RANGE C O M P L E T E Post-Hysterectomy 1,5 Oestrogen only therapy Premenopausal 2,5 Sequential combined therapy Continuous combined therapy Postmenopausal 3,5b (≥= 12 months period free) 8 Applicant&Marketedby:Adcock IngramLimited.Co.Reg.No.1949/034385/06.PrivateBagX69,Bryanston,2021,SouthAfrica.CustomerCare:0860ADCOCK /232625.www.adcock.com . Under licence fromTheramex (Co.Reg.number10944626).2023080210303697August2023. S4 EVOREL®25 (patch).EVOREL® isamatrix type transdermalpatch.EachEVOREL®25 (8cm 2 )patchcontains1,55mgofoestradiol, formulatedas1,6mgofoestradiolhemihydrate.RegNo.:30/21.8.1/0207. S4 EVOREL®50 (patch).EVOREL® isamatrix type transdermalpatchEachEVOREL®50 (16cm 2 )patchcontains3,10mgoestradiol, formulated as3,2mgofoestradiolhemihydrate.RegNo.: Z/21.8.1/339. S4 EVOREL®75 (patch). EVOREL® is amatrix type transdermalpatch. Each EVOREL®75 (24 cm 2 )patch contains4,65mgoestradiol, formulated as4,8mgofoestradiolhemihydrate.RegNo.:30/21.8.1/0208. S4 EVOREL®100 (patch). EVOREL® is amatrix type transdermalpatch.EachEVOREL®100 (32 cm 2 )patch contains6,20mgoestradiol, formulatedas6,4mgofoestradiolhemihydrate.RegNo.:30/21.8.1/0209. S4 EVOREL®SEQUI (patch).EVOREL®SEQUI isa combinationofanoestradiolmatrix type transdermalpatchandanoestradiol/norethisteroneacetatematrix type transdermal patch (sequential regimen). EVOREL® SEQUI is a transdermal therapy comprising: (a)4 EVOREL®50, each containing3,1mgoestradiol, formulated as3,2mgofoestradiolhemihydrate. Each EVOREL®50patchdelivers50µgofoestradiolper24hours. (b)4 EVOREL® CONTI each containing3,1mgoestradiol formulated as3,2mgof oestradiolhemihydrateand9,82mgnorethisterone, formulatedas11,2mgofnorethisteroneacetate.EachEVOREL®CONTIdelivers50µgofoestradioland170µgofnorethisteroneacetateper24hours.EVOREL®SEQUIcontainsnosugar.RegNo.:31/21.8.2/0538. S4 EVOREL®CONTIPatch.EachEVOREL®CONTIcontains3,1mgoestradiol, formulatedas3,2mgofoestradiolhemihydrateand9,82mgnorethisterone, formulatedas11,2mgofnorethisteroneacetate.Thepatchdelivers50µgofoestradioland170µgofnorethisteroneacetateper24hours.EVOREL®CONTI isamatrix type transdermalpatch.EVOREL®CONTIcontainsno sugar.RegNo.:31/21.8.2/0537.For full prescribing information refer topackage insertapprovedby themedicines regulatoryauthority. References: 1. EVOREL® Transdermal Delivery System (TDS) approved professional information, 29 June 2018. 2. EVOREL® SEQUI Transdermal Delivery System (TDS) approved professional information, 6 April 2017. 3. EVOREL® CONTI Transdermal Delivery System (TDS) approved professional information, 17 February 2017. 4. BaberRJ,PanayN,FentonAand the IMSWritingGroup.2016 IMSRecommendationsonwomen’smidlifehealthandmenopausehormone therapy.Climacteric.2016;19(2):109-150.DOI:10.3109/13697137.2015.1129166. 5. BritishMenopauseSociety.Tool for clinicians.HRT-Guide [online] July2020 [cited27 July2023];Available from URL: https://thebms.org.uk/wp-content/uploads/2020/07/04-BMS-TfC-HRT-Guide-JULY2020-01D.pdf. 6. Simon JA, Ravnikar V. Transdermal Estrogen Therapy: Evidence and Update. The Female Patient 2007 (Suppl):1-8. 7. Ravnikar V. Transdermal Estrogen: Clinical Characteristics. The Female Patient. 2007 (Suppl):5-8. 8. MidlarskyE,SegalL.MenopauseDefinition,2018. *Disclaimer:HRTneeds tobe individualisedbasedon risk factorsandwomen’spreferences. 4 TransdermalHRT ispreferredoveroral treatment inwomenwhoareobese,at riskofvenous thromboembolismandat riskof stroke. 4 TransdermalHRTavoidshepaticfirstpassmetabolismandhas several safety benefitsvs.oralHRT. 1,6,7 EVOREL®offersa complete range forwomen fromperi-menopause topost-menopause. 1-3,5 EVOREL ® range gives you the option to meet the needs for pre and postmenopausal women choosing HRT and adopt an individualised approach 1-5 EVOREL ® : Hormone Replacement Therapy (HRT) patchwith a complete range: